期刊文献+

5-氟尿嘧啶节律性化疗对晚期胃癌患者的临床疗效观察 被引量:2

Clinical efficacy of 5-fluorouracil rhythm chemotherapy treating on patients with advanced gastric cancer
下载PDF
导出
摘要 目的观察5-氟尿嘧啶节律性化疗对晚期胃癌患者的临床疗效。方法选择我院24例晚期胃癌患者,使用5-氟尿嘧啶500 mg静脉持续泵入12 h d1-21,4周1个疗程,3~9个疗程后,对接受至少3个疗程的患者进行疗效评价。结果 24例患者随访8~24个月,3例部分缓解(12.5%),9例病情稳定(37.5%),无1例患者完全缓解,12例患者病情进展(50.0%),疾病控制率为50.0%。治疗有效患者的中位疾病进展时间(TTP)为3.2个月。结论 5-氟尿嘧啶节律性化疗可以有效控制老年晚期胃癌患者的病情进展,不良反应少且轻。 Objective To observe the clinical efficacy of 5-fluorouracil rhythm chemotherapy treating on patients with advanced gastric cancer.Methods Choose 24 patients with advanced gastric cancer in our hospital,intravenous continuous infusion 5-fluorouracil 500 mg 12 h d1-21,4 weeks treatment as a course,3~9 courses later,evaluate the clinical efficacy of patients who were received at least 3 courses.Results 24 patients followed up for 8~24 months,3 patients partial remission(12.5%),9 patients stable condition(37.5%),there was no patients complete remission,the rest 12 patients continue to progress(50%),disease control rate was 50%.The median time of progression of the effective treatment patients was 3.2 months.Conclusion 5-fluorouracil rhythm chemotherapy could effective control patients with advanced gastric cancer,adverse reactions are few and mild;Disease control rate.
作者 刘立新
出处 《胃肠病学和肝病学杂志》 CAS 2012年第12期1119-1121,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 5-氟尿嘧啶 节律性化疗 胃癌 临床疗效 疾病控制率 5-fluorouracil Rhythm chemotherapy Gastric cancer Clinical efficacy Disease control rate
  • 相关文献

参考文献8

二级参考文献41

  • 1付生法,陆应麟,张朝山,陈坤.检测血管生长因子作用的鸡胚绒毛尿囊膜技术[J].军事医学科学院院刊,1993,17(4):294-297. 被引量:129
  • 2[6]Nguyen M, Shing Y, Folkman J.Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane[J]. Microvasc Res,1994,47(1):31-40.
  • 3[7]Ribatti D, Vacca A, Presta M. The discovery of angiogenic factors: a historical review[J]. Gen Pharmacol,2000, 35(5):227-236.
  • 4[8]Vacca A, Iurlaro M, Ribatti D et al. Antiangiogenesis is produced by nontoxic doses of vinblastine[J]. Blood, 1999, 94(12):4143-4155.
  • 5[9]Bowder T,Butterfield CE. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer[J]. Cancer Res, 2000, 60(7):1878-1888.
  • 6[10]Ribatti D, Vacca A.The chick embryochorioallantoic membrane as a model for in vivo research on angiogenesis[J]. Int J Devel Biol,1996,40(6):1189-1996.
  • 7Koizumi W.Chemotharepy for advanced gastric cancer:review of global and Japanese status[J].Gastrointest Cancer Res,2007,1(5): 197-203.
  • 8Wagner AD,Grothe W, Haernng J,et al.Chemotherapy in advanced gastric caneer.a systematic review and meta analysis based on aggregate data[J].J Clin Oncol,2006,24(18):2903-2909.
  • 9Hong YS,Song SY, Lee SI,et al.A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer[J].Ann Oncol,2004,15(9): 1344-1347.
  • 10Steinbild S,Arends J,Medinger M,et al.Metmnomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients results of a phase II study[J].Onkologie,2007,30(12):629-635.

共引文献16

同被引文献30

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部